NCT01382225

Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome

A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,936 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.

Conditions

• Dry Eye Syndrome

Interventions

Type	Name	Description
DRUG	Sodium Hyaluronate Ophthalmic Solution, 0.18%
OTHER	Vehicle	Inactive ingredients used as run-in and placebo comparator

Timeline

• Start date: 2011-07-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2011-06-27
• Last updated: 2013-07-08
• Results posted: 2013-07-08